rifamycin SV
有货
英文名称 | rifamycin SV |
---|---|
别名 | Aemcolo |
英文别名 | Aemcolo |
EC号 | 230-273-3 |
---|---|
IUPAC Name | [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate |
INCHI | InChI=1S/C37H47NO12/c1-16-11-10-12-17(2)36(46)38-23-15-24(40)26-27(32(23)44)31(43)21(6)34-28(26)35(45)37(8,50-34)48-14-13-25(47-9)18(3)33(49-22(7)39)20(5)30(42)19(4)29(16)41/h10-16,18-20,25,29-30,33,40-44H,1-9H3,(H,38,46)/b11-10+,14-13+,17-12-/t16-,18+,19+,20+,25-,29-,30+,33+,37-/m0/s1 |
InChi Key | HJYYPODYNSCCOU-ODRIEIDWSA-N |
Canonical SMILES | CC1C=CC=C(C(=O)NC2=CC(=C3C(=C2O)C(=C(C4=C3C(=O)C(O4)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)C |
关联CAS | 6998-60-3,15105-92-7 (mono-hydrochloride salt) |
PubChem CID | 6324616 |
MeSH Entry Terms | Rifamycin;Rifamycins;Rifomycin;Rifomycins |
CAS Registry No. | 6998-60-3 |
---|---|
PubChem CID | 6324616 |
ChEMBL Ligand | CHEMBL437765 |
ChEBI | CHEBI:29673 |
DrugCentral Ligand | 4817 |
Antibiotic DB | 1860 |
Ligand ID | 4570 |
---|---|
名称 | rifamycin SV |
别名 | Aemcolo® |
类别 | Natural product |
学名 | (7S,11S,12R,13S,14R,15R,16R,17S,18S,19Z,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.1^{4,7}.0^{5,28}]triaconta-1,3,5(28),9,19,21,25(29),26-octaen-13-yl acetate |
生物活性评价 |
The sulfonamide class of antibacterial compounds are primarily bacteriostatic agents and have a broad spectrum of activity against both Gram-positive and Gram-negative species of bacteria (reviewed in |
评价 | One of the Ansamycin group of antibacterials. Rifamycin is a natural antibacterial that is produced by Streptomyces mediterranei that exhibits antibacterial and antitubercular properties. Rifamycins are particularly effective against mycobacteria, and are most commonly used to treat tuberculosis, leprosy, and mycobacterium avium complex (MAC) infections. |
1. DuPont HL, Petersen A, Zhao J, Mundt A, Jiang ZD, Miller S, Flores J, Shringarpure R, Moro L, Bagin RG et al.. (2014) Targeting of rifamycin SV to the colon for treatment of travelers' diarrhea: a randomized, double-blind, placebo-controlled phase 3 study.. J Travel Med, 21 (6): (369-76). [PMID:25345982] |
2. Lin SW, Lin CJ, Yang JC. (2017) Rifamycin SV MMX for the treatment of traveler's diarrhea.. Expert Opin Pharmacother, 18 (12): (1269-1277). [PMID:28697313] |